8-K Announcements
6Material company update
May 8, 2026·SEC
Material company update
Apr 3, 2026·SEC
Material company update
Mar 27, 2026·SEC
Entera Bio Ltd.(ENTX)Earnings, Financials & Key Ratios
ENTX•NASDAQ
Price updated Jun 19, 2026
AboutEntera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Show more
- Revenue$42K-76.8%
- EBITDA-$11M-20.5%
- Net Income-$11M-19.9%
- EPS (Diluted)-0.25
- EBITDA Margin-27378.57%-419.5%
- Operating Margin-27450%-418.4%
- Net Margin-27235.71%-416.7%
- ROE-108.01%-4.5%
ENTX Key Insights
Entera Bio Ltd. (ENTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 19 (bottom 19%)
- ✗Sales declining 35.1% over 5 years
- ✗Shares diluted 22.7% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ENTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ENTX Price & Volume
Entera Bio Ltd. (ENTX) stock price & volume — 10-year historical chart
Loading chart...
ENTX Growth Metrics
Entera Bio Ltd. (ENTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-35.11%
3 Years-32.07%
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-22.65%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-164.19%
Return on Capital
10 Years-46.75%
5 Years-88.19%
3 Years-95.3%
Last Year-104.79%
ENTX Recent Earnings
Entera Bio Ltd. (ENTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 2/12 qtrs (100%)
Q2 2026Latest
May 8, 2026Metric
Actual
Est
EPS
$0.07+12.5%
$0.08
Rev
—
—
Q2 2026
Mar 27, 2026Metric
Actual
Est
EPS
$0.07+22.2%
$0.09
Rev
—
—
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.07+22.2%
$0.09
Rev
—
—
Q3 2025
Aug 8, 2025Metric
Actual
Est
EPS
$0.06+45.5%
$0.11
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $0.07vs $0.08+12.5% | — |
| Q2 2026 | Mar 27, 2026 | $0.07vs $0.09+22.2% | — |
| Q4 2025 | Nov 14, 2025 | $0.07vs $0.09+22.2% | — |
| Q3 2025 | Aug 8, 2025 | $0.06vs $0.11+45.5% | — |
Based on last 12 quarters of dataView full earnings history →
ENTX Peer Comparison
Entera Bio Ltd. (ENTX) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ANIP | 1.81B | 79.49 | 23.94 | 43.78% | 9.71% | 17.32% | 0.60 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 AMRN | 333.42M | 16.03 | -8.91 | -6.55% | -15.64% | -7.34% | 0.03 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 CLDX | 2.16B | 32.43 | -8.32 | -78.63% | -345.96% | -50.72% | 0.00 | |
 LLY | 1.04T | 1098.13 | 47.85 | 44.7% | 34.98% | 101.17% | 1.60 | |
 AMGN | 182.2B | 337.60 | 23.72 | 9.92% | 20.95% | 89.41% | 6.31 |
Compare ENTX vs Peers
Entera Bio Ltd. (ENTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ENTX Income Statement
Entera Bio Ltd. (ENTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 500K | 236K | 365K | 571K | 134K | 0 | 181K | 42K | 0 |
Revenue Growth % | - | - | -52.8% | 54.66% | 56.44% | -76.53% | -100% | - | -76.8% | -100% |
Cost of Goods Sold | 43K | 0 | 448K | 300K | 373K | 165K | 56K | 172K | 42K | 15K |
COGS % of Revenue | - | - | 189.83% | 82.19% | 65.32% | 123.13% | - | 95.03% | 100% | - |
Gross Profit | -43K▲ 0% | 500K▲ 1262.8% | -212K▼ 142.4% | 65K▲ 130.7% | 198K▲ 204.6% | -31K▼ 115.7% | -56K▼ 80.6% | 9K▲ 116.1% | 0▼ 100.0% | -15K▲ 0% |
Gross Margin % | - | 100% | -89.83% | 17.81% | 34.68% | -23.13% | - | 4.97% | - | - |
Gross Profit Growth % | -22.86% | 1262.79% | -142.4% | 130.66% | 204.62% | -115.66% | -80.65% | 116.07% | -100% | - |
Operating Expenses | 11.34M | 11.36M | 11.24M | 11.23M | 12.41M | 13.04M | 8.88M | 9.59M | 11.53M | 12.49M |
OpEx % of Revenue | - | 2272.2% | 4763.56% | 3077.53% | 2174.26% | 9729.1% | - | 5300.55% | 27450% | - |
Selling, General & Admin | 8.57M | 2.84M | 4.28M | 4.85M | 5.69M | 7.25M | 4.43M | 5.09M | 5.53M | 5.37M |
SG&A % of Revenue | - | 568.6% | 1813.98% | 1329.04% | 996.5% | 5412.69% | - | 2814.92% | 13154.76% | - |
Research & Development | 2.77M | 8.52M | 6.96M | 6.38M | 6.77M | 5.78M | 4.45M | 4.5M | 6M | 7.12M |
R&D % of Revenue | - | 1703.6% | 2949.58% | 1748.49% | 1185.81% | 4316.42% | - | 2485.64% | 14295.24% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | -46K | 0 | 0 | 0 | 0 | 0 |
Operating Income | 11.34M▲ 0% | -10.86M▼ 195.8% | -11.45M▼ 5.5% | -11.17M▲ 2.5% | -12.22M▼ 9.4% | -13.07M▼ 7.0% | -8.94M▲ 31.6% | -9.59M▼ 7.2% | -11.53M▼ 20.3% | -12.51M▲ 0% |
Operating Margin % | - | -2172.2% | -4853.39% | -3059.73% | -2139.58% | -9752.24% | - | -5295.58% | -27450% | - |
Operating Income Growth % | 311.35% | -195.75% | -5.46% | 2.5% | -9.39% | -6.97% | 31.59% | -7.21% | -20.28% | - |
EBITDA | 11.39M | -10.81M | -11.22M | -11.11M | -12.16M | -13M | -8.88M | -9.54M | -11.5M | -12.48M |
EBITDA Margin % | - | -2161.4% | -4752.54% | -3042.47% | -2130.3% | -9704.48% | - | -5270.17% | -27378.57% | - |
EBITDA Growth % | 313.54% | -194.91% | -3.78% | 0.99% | -9.54% | -6.91% | 31.68% | -7.37% | -20.55% | -24.2% |
D&A (Non-Cash Add-back) | 43K | 54K | 238K | 63K | 53K | 64K | 56K | 46K | 30K | 29K |
EBIT | -11.09M | -10.86M | -10.71M | -11.17M | -12.22M | -12.93M | -8.86M | -9.59M | -11.53M | -12.45M |
Net Interest Income | 0 | 34K | -84K | -28K | -29K | 83K | 31K | 58K | 0 | 12K |
Interest Income | 0 | 34K | 0 | 0 | 0 | 83K | 31K | 58K | 0 | 12K |
Interest Expense | 0 | 0 | 84K | 28K | 29K | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 146K | 557K | 659K | -28K | -29K | 134K | 80K | 58K | 90K | 128K |
Pretax Income | -11.2M▲ 0% | -10.3M▲ 8.0% | -10.79M▼ 4.8% | -11.2M▼ 3.7% | -12.25M▼ 9.4% | -12.93M▼ 5.6% | -8.86M▲ 31.5% | -9.53M▼ 7.5% | -11.44M▼ 20.1% | -12.38M▲ 0% |
Pretax Margin % | - | -2060.8% | -4574.15% | -3067.4% | -2144.66% | -9652.24% | - | -5263.54% | -27235.71% | - |
Income Tax | -146K | 0 | 0 | 20K | -59K | 137K | 29K | 14K | 0 | 0 |
Effective Tax Rate % | 1.3% | 0% | 0% | -0.18% | 0.48% | -1.06% | -0.33% | -0.15% | 0% | 0% |
Net Income | -11.2M▲ 0% | -10.3M▲ 8.0% | -10.79M▼ 4.8% | -11.22M▼ 3.9% | -12.19M▼ 8.7% | -13.07M▼ 7.3% | -8.89M▲ 32.0% | -9.54M▼ 7.3% | -11.44M▼ 19.9% | -12.38M▲ 0% |
Net Margin % | - | -2060.8% | -4574.15% | -3072.88% | -2134.33% | -9754.48% | - | -5271.27% | -27235.71% | - |
Net Income Growth % | -833.86% | 7.98% | -4.77% | -3.9% | -8.66% | -7.25% | 31.99% | -7.33% | -19.89% | -22.65% |
Net Income (Continuing) | -11.2M | -10.3M | -10.79M | -11.22M | -12.19M | -13.07M | -8.89M | -9.54M | -11.44M | -12.38M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.94▲ 0% | -1.29▼ 37.2% | -0.90▲ 30.2% | -0.54▲ 40.0% | -0.47▲ 13.0% | -0.45▲ 4.3% | -0.31▲ 31.1% | -0.25▲ 19.4% | -0.25▲ 0.0% | -0.26▲ 0% |
EPS Growth % | -840% | -37.23% | 30.23% | 40% | 12.96% | 4.26% | 31.11% | 19.35% | 0% | -164.19% |
EPS (Basic) | -1.31 | -0.91 | -0.90 | -0.54 | -0.47 | -0.45 | -0.31 | -0.25 | -0.25 | - |
Diluted Shares Outstanding | 11.9M | 11.51M | 12.15M | 18.42M | 26.13M | 28.81M | 29.01M | 37.65M | 46.19M | 47.76M |
Basic Shares Outstanding | 8.57M | 11.37M | 12.15M | 18.42M | 26.13M | 28.81M | 29.01M | 37.65M | 46.19M | 47.76M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ENTX Balance Sheet
Entera Bio Ltd. (ENTX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 12.42M | 12.47M | 15.64M | 9.11M | 25.33M | 12.85M | 11.26M | 8.97M | 7.11M | 12.49M |
Cash & Short-Term Investments | 11.75M | 11.52M | 15.22M | 8.59M | 24.89M | 12.31M | 11.02M | 8.66M | 7.11M | 4.14M |
Cash Only | 11.75M | 7.51M | 15.22M | 8.59M | 24.89M | 12.31M | 11.02M | 8.66M | 7.11M | 4.14M |
Short-Term Investments | 0 | 4.01M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 725K | 278K | 255K | 183K | 246K | 0 | 126K | 219K | 0 |
Days Sales Outstanding | - | 529.25 | 429.96 | 255 | 116.98 | 670.07 | - | 254.09 | 1.9K | - |
Inventory | 0 | 130K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 182K | 111K | 97K | 163K | 254K | 294K | 238K | 186K | -219K | 8.36M |
Total Non-Current Assets | 861K | 875K | 1.07M | 613K | 658K | 278K | 508K | 418K | 134K | 636K |
Property, Plant & Equipment | 207K | 224K | 462K | 566K | 395K | 229K | 488K | 332K | 134K | 540K |
Fixed Asset Turnover | - | 2.23x | 0.51x | 0.64x | 1.45x | 0.59x | - | 0.55x | 0.31x | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 654K | 651K | 605K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 80K | 90K | 90K |
Other Non-Current Assets | 0 | 0 | 0 | 47K | 46K | 6K | 6K | 6K | -90K | 96K |
Total Assets | 13.28M▲ 0% | 13.34M▲ 0.5% | 16.7M▲ 25.2% | 9.72M▼ 41.8% | 25.99M▲ 167.3% | 13.13M▼ 49.5% | 11.77M▼ 10.4% | 9.39M▼ 20.2% | 15.99M▲ 70.3% | 13.13M▲ 0% |
Asset Turnover | - | 0.04x | 0.01x | 0.04x | 0.02x | 0.01x | - | 0.02x | 0.00x | 0.00x |
Asset Growth % | 111.23% | 0.47% | 25.2% | -41.79% | 167.3% | -49.49% | -10.38% | -20.19% | 70.32% | 251.95% |
Total Current Liabilities | 2.02M | 1.79M | 4.59M | 1.84M | 3.16M | 1.34M | 1.09M | 1.18M | 2.2M | 1.58M |
Accounts Payable | 596K | 473K | 334K | 164K | 166K | 17K | 83K | 132K | 448K | 274K |
Days Payables Outstanding | 5.06K | - | 272.12 | 199.53 | 162.44 | 37.61 | 540.98 | 280.12 | 3.89K | 8.04K |
Short-Term Debt | 0 | 0 | 177K | 189K | 0 | 0 | 0 | 0 | 230K | 185K |
Deferred Revenue (Current) | 0 | 225K | 267K | 158K | 15K | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 995K | 755K | 3.24M | 923K | 455K | 300K | 500K | 339K | 1.52M | 1.12M |
Current Ratio | 6.15x | 6.97x | 3.41x | 4.95x | 8.01x | 9.58x | 10.32x | 7.63x | 3.23x | 7.93x |
Quick Ratio | 6.15x | 6.90x | 3.41x | 4.95x | 8.01x | 9.58x | 10.32x | 7.63x | 3.23x | 7.93x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 42.82M | 1.44M | 192K | 371K | 261K | 32K | 288K | 134K | 689K | 866K |
Long-Term Debt | 3.89M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 260K | 263K |
Capital Lease Obligations | 0 | 0 | 122K | 243K | 123K | 0 | 256K | 102K | 0 | 9K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 38.92M | 1.44M | 70K | 128K | 138K | 32K | 32K | 32K | 429K | 603K |
Total Liabilities | 44.84M | 3.23M | 4.78M | 2.21M | 3.42M | 1.37M | 1.38M | 1.31M | 2.89M | 2.44M |
Total Debt | 3.89M | 0 | 299K | 432K | 302K | 91K | 390K | 272K | 490K | 448K |
Net Debt | -7.85M | -7.51M | -14.92M | -8.16M | -24.59M | -12.22M | -10.63M | -8.39M | -6.62M | -3.69M |
Debt / Equity | - | - | 0.03x | 0.06x | 0.01x | 0.01x | 0.04x | 0.03x | 0.04x | 0.04x |
Debt / EBITDA | 0.34x | - | - | - | - | - | - | - | - | -0.04x |
Net Debt / EBITDA | -0.69x | - | - | - | - | - | - | - | - | 0.30x |
Interest Coverage | - | - | -127.51x | -398.86x | -421.28x | - | - | - | - | - |
Total Equity | -31.56M▲ 0% | 10.12M▲ 132.1% | 11.92M▲ 17.8% | 7.51M▼ 37.0% | 22.57M▲ 200.5% | 11.75M▼ 47.9% | 10.39M▼ 11.6% | 8.08M▼ 22.2% | 13.1M▲ 62.1% | 10.69M▲ 0% |
Equity Growth % | -25% | 132.06% | 17.82% | -36.99% | 200.47% | -47.91% | -11.64% | -22.2% | 62.14% | 255.65% |
Book Value per Share | -2.65 | 0.88 | 0.98 | 0.41 | 0.86 | 0.41 | 0.36 | 0.21 | 0.28 | 0.22 |
Total Shareholders' Equity | -31.56M | 10.12M | 11.92M | 7.51M | 22.57M | 11.75M | 10.39M | 8.08M | 13.1M | 10.69M |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | 1K | 1K | 1K | 1K |
Retained Earnings | -41.81M | -52.12M | -62.91M | -70.24M | -82.43M | -95.5M | -104.39M | -113.93M | -125.37M | -128.87M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 7.4M | 13.06M | 11.44M | 8.96M | 41K | 41K | 41K | 41K | 41K | 41K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ENTX Cash Flow Statement
Entera Bio Ltd. (ENTX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -4.53M | -9.8M | -8.92M | -10.56M | -9.06M | -12.5M | -7.31M | -6.82M | -7.37M | -9.5M |
Operating CF Margin % | - | -1959.2% | -3779.24% | -2892.33% | -1587.22% | -9327.61% | - | -3766.85% | -17547.62% | - |
Operating CF Growth % | -44.05% | -116.44% | 8.95% | -18.37% | 14.15% | -37.91% | 41.52% | 6.73% | -8.1% | -208.74% |
Net Income | -11.2M | -10.3M | -10.79M | -11.22M | -12.19M | -13.07M | -8.89M | -9.54M | -11.44M | -12.38M |
Depreciation & Amortization | 43K | 54K | 238K | 63K | 53K | 64K | 56K | 46K | 30K | 29K |
Stock-Based Compensation | 4.88M | 1.23M | 1.48M | 901K | 1.86M | 2.25M | 1.69M | 2.56M | 2.75M | 0 |
Deferred Taxes | -324K | -41K | 33K | 0 | -217K | 174K | 29K | 14K | 0 | 0 |
Other Non-Cash Items | 1.16M | -232K | -569K | 46K | 18K | -78K | 0 | -5K | 32K | 2.34M |
Working Capital Changes | 909K | -506K | 691K | -351K | 1.41M | -1.83M | -195K | 112K | 1.26M | 508.19K |
Change in Receivables | 0 | -725K | 447K | 23K | 72K | -63K | 246K | -126K | 126K | 7.03K |
Change in Inventory | 0 | 117K | 341K | 0 | -72K | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 543K | -123K | -139K | -147K | 74K | -149K | 66K | 49K | 316K | 159.15K |
Cash from Investing | 1M | -4.07M | 3.95M | -53K | -17K | -102K | -17K | -3K | -107K | -105.48K |
Capital Expenditures | -51K | -68K | -40K | -53K | -17K | -47K | -17K | -3K | -107K | -105.48K |
CapEx % of Revenue | - | 13.6% | 16.95% | 14.52% | 2.98% | 35.07% | - | 1.66% | 254.76% | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 1.05M | -4M | 3.99M | 0 | 0 | -55K | 0 | 0 | 0 | 0 |
Cash from Financing | 11.11M | 9.62M | 12.65M | 4.05M | 25.38M | 13K | 6.04M | 4.48M | 13.71M | 1.33M |
Debt Issued (Net) | -980K | 0 | -114K | -136K | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 12.09M | 9.62M | 12.53M | 3.98M | 21.8M | 13K | 6.62M | 3.96M | 13.71M | 1.33M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 238K | 204K | 3.58M | 0 | -580K | 516K | 0 | 0 |
Net Change in Cash | 7.58M▲ 0% | -4.24M▼ 155.9% | 7.68M▲ 281.1% | -6.56M▼ 185.4% | 16.3M▲ 348.5% | -12.58M▼ 177.2% | -1.29M▲ 89.7% | -2.35M▼ 81.6% | 6.23M▲ 365.8% | -8.65M▲ 0% |
Free Cash Flow | -4.58M▲ 0% | -9.86M▼ 115.5% | -8.96M▲ 9.2% | -10.61M▼ 18.4% | -9.08M▲ 14.4% | -12.55M▼ 38.2% | -7.33M▲ 41.6% | -6.82M▲ 6.9% | -7.48M▼ 9.6% | -9.61M▲ 0% |
FCF Margin % | - | -1972.8% | -3796.19% | -2906.85% | -1590.19% | -9362.69% | - | -3768.51% | -17802.38% | - |
FCF Growth % | -43.8% | -115.51% | 9.17% | -18.43% | 14.42% | -38.17% | 41.6% | 6.91% | -9.62% | -50.81% |
FCF per Share | -0.38 | -0.86 | -0.74 | -0.58 | -0.35 | -0.44 | -0.25 | -0.18 | -0.16 | -0.20 |
FCF Conversion (FCF/Net Income) | 0.40x | 0.95x | 0.83x | 0.94x | 0.74x | 0.96x | 0.82x | 0.71x | 0.64x | 0.78x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 89K | 2K | 0 | 0 | 0 | 0 | 0 |
ENTX Key Ratios
Entera Bio Ltd. (ENTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -101.86% | -97.98% | -115.46% | -81.04% | -76.17% | -80.3% | -103.34% | -108.01% | -87.97% |
Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | - | -280.06% | -139.19% |
Gross Margin | - | 100% | -89.83% | 17.81% | 34.68% | -23.13% | - | 4.97% | - | - |
Net Margin | - | -2060.8% | -4574.15% | -3072.88% | -2134.33% | -9754.48% | - | -5271.27% | -27235.71% | - |
Debt / Equity | - | - | 0.03x | 0.06x | 0.01x | 0.01x | 0.04x | 0.03x | 0.04x | 0.04x |
Interest Coverage | - | - | -127.51x | -398.86x | -421.28x | - | - | - | - | - |
FCF Conversion | 0.40x | 0.95x | 0.83x | 0.94x | 0.74x | 0.96x | 0.82x | 0.71x | 0.64x | 0.78x |
Revenue Growth | - | - | -52.8% | 54.66% | 56.44% | -76.53% | -100% | - | -76.8% | -100% |
Related:ENTX Dividend History·ENTX Revenue History·ENTX Price History·ENTX P/E History·ENTX Financial Ratios·ENTX Institutional Holders
ENTX SEC Filings & Documents
Entera Bio Ltd. (ENTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
ENTX Frequently Asked Questions
Entera Bio Ltd. (ENTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Entera Bio Ltd. (ENTX) reported $0.0M in revenue for fiscal year 2025.
Entera Bio Ltd. (ENTX) saw revenue decline by 76.8% over the past year.
Entera Bio Ltd. (ENTX) reported a net loss of $12.4M for fiscal year 2025.
Dividend & Returns
Entera Bio Ltd. (ENTX) has a return on equity (ROE) of -108.0%. Negative ROE indicates the company is unprofitable.
Entera Bio Ltd. (ENTX) had negative free cash flow of $9.6M in fiscal year 2025, likely due to heavy capital investments.